Why this matters now
The pharma sector straddles health and economy — its strengths (generics, vaccines), the API import dependence, drug pricing and regulation are all tested in GS-2/GS-3.
Strengths of the sector
India is the largest provider of generic drugs globally and a top vaccine producer (e.g. the Serum Institute), supplying affordable medicines to India and the world (including under programmes like Jan Aushadhi). The sector is a major exporter and employer, central to global health security.
Regulation and pricing
Drugs are regulated by the CDSCO (Central Drugs Standard Control Organisation) under the Drugs and Cosmetics Act; the NPPA caps prices of essential medicines (via the DPCO and the National List of Essential Medicines). Jan Aushadhi Kendras sell low-cost generics.
Challenges and the way forward
Key challenges: heavy import dependence for APIs/bulk drugs (mainly from China), ensuring drug quality and curbing substandard/spurious drugs, R&D and innovation gaps, and antimicrobial resistance. The response: PLI schemes for APIs and bulk drugs, bulk-drug parks, and a push for R&D and self-reliance.
UPSC angle
Know India as the generics/vaccine leader, CDSCO (regulator) and NPPA/DPCO (pricing), Jan Aushadhi, the API import dependence (China), and PLI/bulk-drug parks for self-reliance.
Frequently asked questions
Why is India called the pharmacy of the world?
Because it is the largest global supplier of affordable generic medicines and a major vaccine producer.
Who regulates drugs in India?
The Central Drugs Standard Control Organisation (CDSCO) under the Drugs and Cosmetics Act.
Who controls drug prices in India?
The National Pharmaceutical Pricing Authority (NPPA), which caps prices of essential medicines via the DPCO.
What is the main vulnerability of India’s pharma sector?
Heavy import dependence for Active Pharmaceutical Ingredients (APIs), mainly from China.